NURS 6630Wk 9 Bode-Oloye Assign 8 ADHD Anuoluwapo Bode-Oloye NURS 6630 Psychopharmacology Attention Deficit Hyperactivity Disorder NURS 6630Wk 9 Bode-Oloye Assign 8 ADHD Anuoluwapo Bode-Oloye NURS 663

************************************** ************** **** *************************** ******* Hyperactivity ************************************* ******* Hyperactivity ******** (ADHD)ADHD ** a *************** ******** ************* *************** ************* ****** ** inattention *** ******** ****** ** **** on *** ** ******* *** been *********** resulting ** ****** **** ******* ** **** income and ************ ***** ******** *** adolescents *** **** *** ** & ******** ***** ADHD is * ****** ********** ********** ******* in ********* primary **** with *** prevalence estimate ******** at 72% (Moore ** al ***** ****** ************ *** ********** **** of ********** ********** *** most children with **** *** problem *********** ** ***** ******** ***** **** *************** making and *********** *********** peer rejection *** ******* *** increased negative **** and ********* interactions ******* ** ** 2018) ******** ****** functioning ** viewed ** one of the **** ******** *** children with **** *** ******** with **** present **** ************ ** *** following domains ***** includes *************** planning ********** orienting ******** ********** continued ********* and ******* ****** ******** et ** 2018)Decision * ****** Ritalin (methylphenidate) chewable ******* ** mg orally ** the ********************** (MPH: ******** is adrug **** *** the ********* of attention ******* ************* ******** ****** *** ** frequently used ** a cognitive enhancer *** ************ is ********* **** immediate ******* formulations to titrate *** **** depending on *** ********** ****** duration *** ******** ** symptoms ********** ******* &Blike-Hentsch ***** *** increases *** dopamine release by blocking the ** transporter in the human ******** (Tohru ** ** ***** *** ** **** ** enhance ********* *** ********* **** performance ** ***** ** the ***** ** ***** ******* ******* ** *** **** ******** ********** of *** ********** ****** ***** ****** ****** ********* ******** ** associated **** ******** ******* ****** performance ****** ** ** ******** goal ** *** ********* is to reduce *** symptoms ** *************** ***** ************* *** ************* **** ******* ****** school *** ************ *********** (Stahl ************** et ** (2017) ********* **** upon initiation of **** therapy **** ** without ******* treatment *** *********** ** **** the **** symptoms ** **** **** decrease *** *** ******* will no longer ********** ********** ******** ** social ************ *** ******** ******* ** *** **** ********** **** *** ****** ****** quickly ***** the ********** ** medication ******* ********** ** ** ********** ** no ******** ** *** results obtained **** the ******* ** *** ******** **** *** *** expected outcomes ** **** ** *** case ***** *** ******** *********** ** this ******* ******* ******** with *** use of ******* ****** *** **** the medication ******* its **** *** ***** *** **** *** patient’s ****** as ********* by her ********** *** **** ******** *** ***************** ** *** ********* Another **** ****** ******** ** the follow-up visit *** **** the ******* *** ************ *********** ** evidenced ** the ****** ** *** ************ **************** #2Change ** Ritalin ** ** ** ****** ***** ** the *********** the **** ******* reported by the ******* ** *** **** ***** ** was ********* to ****** *** dosage ** *** Ritalin ** * *********** ****** **** ***** ** *** ****** ********* ** al ****** ****** that ***** *** *********** dose ** ********** ******** *** often ******** to * *********** *********** ***** ** **** ** ***** **** intake ** school ***** presence ** ***** ******** ********** *** ********** ** effects (Haertling et ** ***** ******* Duan& ****** ****** ********* that ********** extended release MPH ************ *** **** ******** ** ******* *** ******* ********** behavior improvements ********** *** day with * ****** **** (Xiaoxia ** ** ***** ** **** **** the patient *** ****** some **** effects **** *** ********* ******* ************* ********** *** ******* off ****** *** *** ** *** ****** day *** this patientand *** ****** something long-lasting ** **** *** ******** lowThe **** ** ** improve ******** *** *** ******* ** **** ** *** patient *** reasonable ******** ******** is ** ******* ** ** ******** ******* response ******** ** ** 2013) In ** ************* study which *** ******** ** ******** *** ******** ** Ritalin ** to ******** **** ADHD ***** ******* practice ********** ** ******* ************ **** *** medication ******** *** **** ******** ** *** ******* *** *** ******* ** **** ** **** ******* (Haertling ** ** ***** The ********* ** expected *** *** *** ******* ** this case ***** *** patient ** ********* ** ******** the ********** ****** **** a ****** ****** ** ******** than *** ******** ********* (Haertling et ** 2015)No ********** in *** ******** outcome *** *** outcome ** *** ******** **** in the ******* ** *** case ***** ** *** mentioned **** ***** ******* **** ***** follow ** *** ******* ******** an ********** *********** because *** ** *********** ** ******* *** ******* ********** *** ****** *** **** ******** **** ********** good ******* ******* ****** the **** ** *** *** ** *** ******* adjustments ** **** * ****** ** *** formulation ** ****** ** a ********* ***** ** **** *** ** ******** ******** ** al ************* ********** current **** of ******* ** *** ********** ** * ******** reason *** decision *** **** *** ** ******** *** treatment ******* ** ** ******* *** **** patient There ** **** the need to monitor and ********** *** patient for ***** response ** ********** ***** ****** mentioned that *** goal is ** continue treatment until *** symptoms *** ***** ******* ** *********** ** stable Treatment *** ** continueduntil ******* ****** if improvement persists ********** *** **** *** ********** ********* (Stahl ******** ******** outcome ** ** ******* *** efficacy of *** medication *** patient is ****** ** ****** the **** ******* ** experienced ** *** patient *** ********* needs to ******* *********** ***** *** **** ******** *** *** *** that the ******* changes ****** *** *********** et al ***** ** ** ************* ** ******* of *** *********** ******* ************ **** trying to optimize *** treatment *** *** patient **** approach **** **** to ******** clinical **** and ***** ****** ** ***** ******** that ******** ******** *********** ******* ******** et al 2013)There ** ** ********** ******* *** ******** ******* *** *** results ** the decision made ******* ** ** ****** stated **** ********* ******** **** ********* treatment ***** and responses ** MPH ** ******* *** treatment of **** ********* * ******** ******** to ********* is ********** ** imperative ** ***** ******** *** ********** *** ******* ********** *** day (Coghill ** ** ************ ************** ** *** ********* planAdherence ** prescribed ********* ** important for *** ******* ofany *********** ************ *** ***** ****** ************ ******* ********* as * ****** to which a ********** ******** *********** **** the agreed recommendations **** * ********** ******** ********* ********* *** patient’s ******** ** act ** *** *** **** will **** **** ****** ******* with *** *********** **** ** their ********* ************ ** ********* ** * ****** ***** ** medical ******* ********* ********** * *********** adherence ** a ********* **** ******* full disclosure ** *** ********** plan requires protecting *** *********** ****** ****** et ** ***** For *** ******* her ****** ***** have ** **** **** *** ** compliant **** ****** *** medication as prescribed because she is * minorReferencesArcangelo * P ******** * * Wilbur V ***** Reinhold * A ***** (2017) ******************** *** ******** ********* * ********* ******** **** *** Ambler PA: ********** ******** ***** ************** * ********* * **** * ************* * ***** Speyer * (2018) **** ********* ** ************* *** ******** **** ***** A Systematic ****** *** Meta-Analysis ****** Research International **** ****************************** D Banaschewski * ****** * Pelaz * ******** * &Doepfner M ****** Long-acting methylphenidate formulations ** *** ********* of ******************************* disorder: * ********** ****** of head-to-head ******* BMC ********** ***** **** doi:101186/1471-244X-13-237Haertling * Mueller * &Bilke-Hentsch * ******** ** 2015) ************* *** ****** ** * *********** ********** two-phase ******* *********** ** methylphenidate ********** *** in school children ***** daily ******** ********** Adhd ********* Deficit *** ************* ********* * * ************* * * Harmon * L ***** * * *** T * Austin * E Spiegel * * ***** ****** D E ****** ************** *** ********** predictors ** social problems ** ***** * ******** ********* Neuropsychology 32(3) ******* doi:101037/neu0000416Li J * & ******** * * ****** A **************** ********** ********* ********** of ******** ********** ************ ************ with ******** ****** *** child **** ******** Developmental ********** ************************** * * ***** * Sherina V ******* * *** S ***** Garfunkel * C (2018) Practice ********** ** models ** ******* **** ************* *** ******** with **** Families ******* ***** Health ***** 73-86 ************************** * * Moore B A ****** * * & ******* * R ****** ******* considerations ** ********* ******** ******* ********** & ********* *********** ************************** * * ******* *** ************** guide **** *** New **** NY: ********* ********** PressTohru * Takashi * ******* * ******** * Ken-ichiro * ************* * ****** **** Administration ** *************** (Ritalin) ******* Dopamine ******* Differentially ******* the ********** ****** *** Striatum: * Microdialysis ***** in *** ****** ******* ** ************ ***** 2387-2394 ************************************** Y **** * ***** ****** * (2016) *********** ** Physiologically ***** ********** Modeling ** ************ *** *************** ******** of **** ******** Release *************** ******** ** ****** **** *** ****** **** *******************************

Click here to download attached files: Attention-Deficit-Hyperactivity-Disorder-(ADHD). (3).docx